ipilimumab (MDX-010, BMS-734016)

DRUG2 trials

Sponsors

Bristol-Myers Squibb

Conditions

Melanoma

Phase 2

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

CompletedNCT00289627

Bristol-Myers SquibbMelanoma

Start: 2006-04-30End: 2007-07-31Updated: 2016-09-28

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

CompletedNCT00289640

Bristol-Myers SquibbMelanoma

Start: 2006-04-30End: 2007-07-31Target: 210Updated: 2010-03-02

Related Papers

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

2009-12-08898 citations

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

2009-01-13214 citations